Allarity enrolls first patient in Phase 2 stenoparib trial for advanced ovarian cancer

Allarity Therapeutics, Inc.

First patient dosed in new Phase 2 protocol for platinum-resistant or platinum-ineligible advanced ovarian cancer.
Trial includes DRP companion diagnostic to enrich for stenoparib responders.
Two patients remain on prior Phase 2 study on twice-daily dosing, deriving benefit beyond 20 months.
Additional dosing level added aligning with FDA Project Optimus to inform pivotal trial design.
Company expects significant clinical data by late summer 2026; pursuing accelerated regulatory pathways.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.